摘要
目的观察康艾注射液联合PP化疗方案治疗脾肺气虚型晚期肺腺癌患者的疗效、不良反应以及对血清癌胚抗原(CEA)和中医证候的影响。方法脾肺气虚型晚期肺腺癌者91例,分为治疗组和对照组,治疗组采取康艾注射液联合PP方案(顺铂/卡铂+培美曲塞)化疗,对照组单用PP方案(顺铂/卡铂+培美曲塞)化疗,21 d为一个周期,共接受2~6个周期的治疗。评价近期疗效,记录不良反应发生情况,检测治疗前后血清CEA水平,观察中医证候改善情况。结果治疗组和对照组疾病控制率分别为85.71%的83.33%,客观缓解率分别为42.86%和30.95%,差异无统计学意义(P>0.05);治疗组不良反应发生率低于对照组(P<0.05);两组CEA治疗后较治疗前均下降,两组下降情况差异无统计学意义(P>0.05);治疗组中医证候总有效率97.62%,改善情况优于对照组73.80%(P<0.05)。结论康艾注射液能够降低化疗带来的不良反应,改善晚期肺腺癌患者的中医证候。
Objective To observe the efficacy,adverse events and the influence on carcino embryonic antigen(CEA)and traditional chinese medicine(TCM)syndromes of Kangai injection combined with chemotherapy in the treatment of patients with advanced lung adenocarcinoma of spleen-lung qi deficiency type.Methods 91 patients with advanced lung adenocarcinoma of spleen-lung qi deficiency type were enrolled and divided into treatment group and control group.The treatment group was treated with Kangai injection combined with a pemetrexed/cisplatin(PP)regimen for chemotherapy,while the control group was treated with PP regimen alone for 21 days as a cycle and received 2~6 cycles of treatment.The short-term therapeutic effects were evaluated,the occurrence of adverse reactions were recorded,serum CEA levels before and after treatment were detected,and the improvement of TCM syndromes were observed.Results The disease control rates of the treatment group and control group were 85.71%and 83.33%,respectively;the objective response rates were 42.86%and 30.95%,respectively,without statistical significance(P>0.05).The incidence of adverse events in the treatment group was lower than that in the control group(P<0.05).CEA levels in both groups decreased after treatment,but there was no statistical difference between the two groups(P>0.05).The total effective rate of TCM syndromes in the treatment group was 97.62%,and the improvement was better than 73.80%in the control group(P<0.05).Conclusion Kangai injection can reduce the adverse events caused by chemotherapy and improve the TCM syndromes of patients with advanced lung adenocarcinoma.
作者
朱诗聪
王鹤玲
徐娅
陈建华
章必成
ZHU Shicong;WANG Heling;XU Ya;CHEN Jianhua;ZHANG Bicheng(The First Clinical College of Hubei University of Traditional Chinese Medicine, Wuhan 430065, China;Medical College, Wuhan University of Science and Technology,Wuhan 430081,China)
出处
《医药导报》
CAS
北大核心
2020年第4期572-576,共5页
Herald of Medicine
关键词
康艾注射液
肺腺癌
化学治疗
脾肺气虚
Kangai injection
Lung Adenocarcinoma
Chemotherapy
Spleen-lung Qi dificiency
